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ORIGINAL RESEARCH
Invasive Hemodynamic Monitoring in 
Cardiogenic Shock Is Associated With 
Lower In- Hospital Mortality
Mohammed Osman , MD; Moinuddin Syed, MD; Brijesh Patel, DO; Muhammad Bilal Munir , MD;  
Babikir Kheiri , MD, MSc; Marco Caccamo , DO; George Sokos, DO; Sudarshan Balla , MD;  
Mir Babar Basir, DO; Navin K. Kapur , MD; Mamas A. Mamas , MD; Christopher M. Bianco, DO
BACKGROUND: There is increasing utilization of cardiogenic shock treatment algorithms. The cornerstone of these algorithms is 
the use of invasive hemodynamic monitoring (IHM). We sought to compare the in- hospital outcomes in patients who received 
IHM versus no IHM in a real- world contemporary database.
METHODS AND RESULTS: Patients with cardiogenic shock admitted during October 1, 2015 to December 31, 2018, were identi-
fied from the National Inpatient Sample. Among this group, we compared the outcomes among patients who received IHM 
versus no IHM. The primary end point was in- hospital mortality. Secondary end points included vascular complications, major 
bleeding, need for renal replacement therapy, length of stay, cost of hospitalization, and rate of utilization of left ventricular 
assist devices and heart transplantation. Propensity score matching was used for covariate adjustment. A total of 394 635 
(IHM=62 565; no IHM=332 070) patients were included. After propensity score matching, 2 well- matched groups were com-
pared (IHM=62 220; no IHM=62 220). The IHM group had lower in- hospital mortality (24.1% versus 30.6%, P<0.01), higher 
percentages of left ventricular assist devices (4.4% versus 1.3%, P<0.01) and heart transplantation (1.3% versus 0.7%, P<0.01) 
utilization, longer length of hospitalization and higher costs. There was no difference between the 2 groups in terms of vascular 
complications, major bleeding, and the need for renal replacement therapy.
CONCLUSIONS: Among patients with cardiogenic shock, the use of IHM is associated with a reduction in in- hospital mortality 
and increased utilization of advanced heart failure therapies. Due to the observational nature of the current study, the results 
should be considered hypothesis- generating, and future prospective studies confirming these findings are needed.
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Cardiogenic shock (CS) is a life- threatening con-dition characterized by acute end- organ hy-poperfusion due to inadequate cardiac output, 
resulting in multi- organ failure culminating in death.1- 4 
Contemporary data from specialized cardiogenic 
shock centers shows that early recognition and algo-
rithmic approaches for managing CS with the rapid 
deployment of MCS are associated with a reduc-
tion in mortality.5- 7 Invasive hemodynamic monitoring 
(IHM) is the cornerstone of such treatment algorithms, 
emphasizing early diagnosis and phenotyping of 
CS. The ESCAPE (Evaluation Study of Congestive 
Heart Failure and Pulmonary Artery Catheterization 
Effectiveness) trial reported a lack of benefit with IHM. 
Since then, there has been a decreasing trend in IHM 
use among patients admitted with congestive heart 
failure and cardiogenic shock.8- 13 It is essential to high-
light that studies evaluating the role of IHM; includ-
ing the ESCAPE trial, excluded patients with CS and 
were conducted before the current era of advances in 
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MCS.11,14,15 Using a large nationally representative sam-
ple of patients with CS, we sought to determine the 
impact of IHM use, as well as the timing of use, on clin-
ical outcomes including in- hospital mortality among 
patients admitted with CS.
METHODS
Study Data
The study was derived from the National Inpatient 
Sample (NIS), from October 1, 2015 to December 31, 
2018. The NIS database is part of the Healthcare Cost 
and Utilization Project (HCUP) databases and is spon-
sored by the Agency for Healthcare Research and 
Quality (AHRQ).16 The NIS is the largest publicly avail-
able all- payer administrative claims- based database 
and contains patient discharges from 1000 hospitals 
in 45 states. It has clinical and resource utilization in-
formation on more than 7 million discharges annually. 
Weighted, it represents more than 35 million hospitali-
zations nationally on an annual basis. These data are 
stratified to represent 20% of US inpatient hospitaliza-
tions across different hospital and geographic regions 
(random sample).16 Institutional review board approval 
and informed consent were not required for this study, 
given the NIS database’s de- identified nature and pub-
lic availability. Because of the sensitive nature of the 
data collected for this study, requests to access the 
data set from qualified researchers trained in human 
subject confidentiality protocols may be sent to the 
Healthcare Cost and Utilization Project at https://www.
hcup- us.ahrq.gov/tech_assis t/centd ist.jsp.
Study Population
Adult patients (≥18  years) admitted with CS during 
October 1, 2015 to December 31, 2018, were identi-
fied in the NIS using the International Classification 
of Disease, Tenth Revision Clinical Modification Code 
(ICD- 10- CM) R570, which was applied to all the diag-
noses variables provided by the dataset. We then iden-
tified patients who underwent IHM during the same 
admission using the ICD- 10 procedure codes (ICD- 
10- PCS) 4A1239Z, 4A0239Z, 4A023N6, 4A023N8, 
4A033J3, 4A033B3, 4A03353, 4A13353, 4A133B3, 
4A133J3, and 02HP32Z, which codes for measure-
ment, monitoring, or insertion of monitoring device to 
check cardiac output or pulmonary artery hemody-
namics. Similar methods were used in previous studies 
to identify patients who received IHM.10,12,17 The com-
plete list of the codes used in the current analysis is 
provided in Table S1.
We excluded patients who underwent only left 
heart catheterization without accompanying right heart 
catheterization. Furthermore, we excluded the follow-
ing patients: (1) patients with missing mortality, age, or 
sex data, (2) patients who were younger than 18 years, 
(3) patients who received concomitant cardiac surgery 
(coronary artery bypass grafting or valve surgery), tran-
scatheter aortic valve replacement, mitral clip or cathe-
ter ablation during the same hospitalization, (4) patients 
who died on the day of admission, (5) patients with the 
diagnosis of primary pulmonary hypertension, (6) pa-
tients who were admitted electively to the hospital, and 
(7) patients who received the IHM after or on the same 
day of receiving durable left ventricular assist devices 
(LVADs) or heart transplantation (HT).
We have conducted several analyses on the in-
cluded population as follows: (1) a primary analysis 
comparing the in- hospital outcomes among patients 
who received IHM versus no IHM, (2) a secondary 
analysis assessing the impact of the timing of IHM 
on in- hospital outcomes; this was performed by con-
structing 3 different matched cohorts to compare the 
outcomes among patients who received early IHM 
(eIHM) (within the first 24 hours) versus delayed IHM 
dIHM (after the first 24 hours and up to a week) and ver-
sus matched controls (no IHM), (3) sensitivity analysis 
by stratifying the primary outcome based on the type 
of the CS (acute myocardial infarction- CS [AMIC- CS or 
Non- AMI- CS]), (4) sensitivity analysis by restricting the 
CLINICAL PERSPECTIVE
What Is New?
• Among patients with cardiogenic shock, the 
use of invasive hemodynamic monitoring is as-
sociated with a reduction in in- hospital mortality 
and increased utilization of durable left ventricu-
lar assist devices and heart transplantation.
What Are the Clinical Implications?
• The use of invasive hemodynamic data to guide 
the care of patients with cardiogenic shock is 
associated with reduced in- hospital mortality.
• Treatment protocols relying on invasive hemo-
dynamic data in patients with cardiogenic shock 
should be further studied in randomized clinical 
trials.
Nonstandard Abbreviations and Acronyms
AHRQ Agency for Healthcare Research and 
Quality
CS cardiogenic shock
IHM invasive hemodynamic monitoring
NIS National Inpatient SampleDow
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included cohort to patients who received an indwelling 
pulmonary artery catheter (PAC). Following methods 
used in previous studies, the PAC cohort was isolated 
by identifying patients who received codes for moni-
toring or insertion of monitoring device to check car-
diac output or pulmonary artery hemodynamics,10 and 
(5) sensitivity analysis by excluding patients who died 
within 72 hours of admission. Additionally, as previous 
studies suggested disparity in the management and 
outcomes of CS, we have conducted several sub-
groups analyses for the primary outcome based on 
demographic groups to detect heterogeneity of the 
treatment effect among the different subgroups as fol-
lows: (1) a subgroup analysis stratified by sex, (2) a sub-
group analysis stratified by race, and (3) a subgroup 
analysis stratified by age.18,19
Additionally, due to the study’s observational nature, 
we estimated the strength of unmeasured confounding 
using the E- Value methodology of VanderWheel and 
Ding.20 This method estimates the minimum strength 
of the association that would be required between an 
unmeasured confounder and both exposure (IHM) and 
outcome (in- hospital mortality) to overcome the sta-
tistically significant effect observed in a study where 
residual confounding is a potential problem. The cal-
culation was derived from the odds ratio obtained from 
the analysis after applying propensity score matching. 
Moreover, we used falsification end points analysis to 
further guard against residual confounders. In falsi-
fication analysis, one or more end points thought to 
be unrelated to the exposure of interest (IHM) are pre-
specified. The association between the exposure and 
outcome is tested after adjustment for confounders. 
The presence of any spurious association between 
the exposure and outcome suggests that the current 
analysis is prone to bias from unmeasured confound-
ers.21,22 For the present study, we used 2 separate 
falsification end points, including catheter- associated 
urinary tract infection and sacral decubitus ulcers.
Study End Points
The primary end point of this study was in- hospital 
mortality. Secondary end points included vascu-
lar complications, major bleeding (defined as post- 
procedural bleeding requiring blood transfusion), need 
for renal replacement therapy (RRT), resources utiliza-
tion surrogates (length of stay and cost of hospitaliza-
tion), and utilization of advanced heart failure therapies 
(LVADs and HT). The need for RRT was considered to 
be present after excluding patients who are dialysis- 
dependent to isolate patients with a new requirement 
for RRT during the hospitalization. We also reported 
the percentage of patients with a concomitant code 
for bloodstream infection in the 2 groups as a safety 
end point.
Statistical Analysis
All variables are expressed as weighted national es-
timates. This was done following the survey analysis 
method by incorporating the (HOSP_NIS) as a cluster-
ing variable and accounting for the different strata in 
the NIS design using the (NIS_STRATUM) as recom-
mended in the AHRQ methods series.16 Categorical 
variables were expressed as count (percentage) 
and compared using the Scott- Rao Chi- square test. 
Continuous variables were expressed as median (in-
terquartile range) and compared using the Wilcoxon 
rank- sum test.
Moreover, for the primary analysis, a propensity 
score- matching (PSM) Model was calculated using 
multivariate logistic regression to derive 2 matched 
groups for comparative outcomes analyses (IHM ver-
sus no IHM). A nearest- neighbor 1:1 variable ratio, 
parallel, balanced propensity- matching model was 
applied using a caliper width of 0.01. The variables in-
cluded in the PSM model included demographics (age, 
sex, and race), comorbidities (hypertension, diabetes 
mellitus, chronic kidney disease, chronic heart failure, 
peripheral vascular disease, chronic lung disease, can-
cer, chronic liver disease, coagulopathy, prior stroke, 
smoking, and obesity), clinical factors (AMI- CS or need 
for mechanical ventilation or percutaneous coronary 
intervention), MCS use, and hospital characteristics 
(hospital bed size and teaching status). Moreover, the 
same PSM model was used to derive 3 more compar-
ative cohorts to compare the outcomes among (eIHM 
versus dIHM), (eIHM versus no IHM), and (dIHM versus 
no IHM).
Additionally, multivariable risk adjustments using 
several models derived from generalized structured 
equation modeling to account for the clustering of data 
within different hospitals were used to assess the im-
pact of various confounding factors on the primary end 
point as follows: Model (1) adjusted for demographic 
and clinical comorbidities; Model (2) adjusted for de-
mographic, comorbidities and clinical factors; Model 
(3) adjusted for demographic, clinical comorbidities, 
clinical presentation on admission, and hospital char-
acteristics; Model (4) adjusted for demographic, clinical 
comorbidities, clinical presentation on admission, hos-
pital characteristics, and MCS use; and Model (5) ad-
justed for demographic, clinical comorbidities, clinical 
presentation on admission, hospital characteristics, 
MCS use, and advanced heart failure therapies. Within 
model 5, we tested for interaction between IHM and 
advanced heart failure therapies. We used the cost- to- 
charge ratio files provided by the HCUP to convert the 
hospital charges to more accurate hospital costs for 
cost calculations. A P value of <0.05 was considered 
statistically significant. For statistical analyses, we used 
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26 (IBM Corp) and R, version 3.5 for the main analy-
sis and propensity matching, respectively. Additionally, 
we used Stata Statistical Software: Release 15 (Stata- 
Corp. 2017) to build the models for adjusted analysis 
using generalized structured equation modeling.
RESULTS
A total of 394  635 (IHM=62  565; no IHM=332  070) 
patients qualified to be included in the current analy-
sis. The flow chart of the study is shown in Figure 1. 
Comparing patients who underwent IHM to no IHM, 
IHM patients were younger (64 years [IQR 55– 72] versus 
68 years [IQR 58– 78], P<0.01), less likely to be females 
(33.1% versus 38.6%, P<0.01), had higher prevalence 
of chronic heart failure (36.3% versus 27.9%, P<0.01), 
chronic kidney disease (39.2% versus 36.8% P<0.01), 
obesity (19.4% versus 17.7%, P<0.01), and coagulopa-
thy (25.5% versus 22.7%; P<0.01). Moreover, the IHM 
had higher utilization of percutaneous coronary inter-
ventions (PCI) (23.9% versus 18.6%; P<0.01). On the 
other hand, IHM patients had lower prevalence of met-
astatic cancer (1% versus 2.3%, P<0.01), chronic lung 
disease (24.2% versus 27.6%, P<0.01), and prior stroke 
(8.3% versus 9.2%, P<0.01). A detailed description of 
the baseline characteristics is shown in (Table 1).
After PSM, 2 well- matched IHM and no IHM groups 
were compared (n=62  220 for each group) (Table  2). 
After PSM, standardized mean differences were re-
duced to <10% for all the covariates, indicating a bal-
anced population. The variables used in the PSM and 
the result of the PSM are shown in Figure 2. The IHM 
group showed lower in- hospital mortality (24.1% versus 
30.6%, P<0.01, OR 0.7 [95% CI 0.67– 0.74]) with higher 
utilization of LVADs (4.4% versus 1.3%, P<0.01) and HT 
(1.3% versus 0.7%, P<0.01) longer length of hospitaliza-
tion (median=11 versus 7 days, P<0.01) and higher costs 
(median=45 511$ versus 31 290, P<0.01). There was no 
difference between the 2 groups in terms of vascular 
complications, major bleeding, and the need for RRT 
(Table 2). There was a consistent reduction in in- hospital 
mortality in all the subgroups with no detected hetero-
geneity (Figure 3). Moreover, in the sensitivity analysis, 
the association of IHM with reduced mortality persisted 
in both AMI- CS (IHM=30.8% versus no IHM=34%, 
P<0.01) and non- AMI- CS groups (IHM=19.4% versus 
Figure 1. Flow chart of the study.
CS indicates cardiogenic shock; IHM, invasive hemodynamic monitoring; LVAD, left ventricular assist devices; TMVR, transcatheter 
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Figure 2. Dot plot showing covariates balance before and after the propensity matching.
AMI indicates acute myocardial infarction; MCS, mechanical circulatory support; and PCI, percutaneous 
coronary intervention. *Overall balance represents the average standardized mean difference for all the 
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no IHM 37.4%, P<0.01). Additionally, in the sensitivity 
analyses in which patients who died within 72  hours 
were excluded or the analysis was restricted to the PAC 
cohort, the association of IHM with reduced in- hospital 
mortality remained statistically significant (IHM=18.1%, 
no IHM=20%, P<0.01) and (PAC=28%, no PAC=31%, 
P=0.02), respectively. The IHM group had a higher per-
centage of bloodstream infection than the no IHM group 
(0.6% versus 0.4%, P<0.01).
In the risk- adjusted analyses, the use of IHM contin-
ued to be associated with lower in- hospital mortality. 
In model 1, adjusting for demographics and comor-
bidities, the utilization of IHM was associated with re-
duced in- hospital mortality (adjusted odds ratio [aOR] 
0.60, 95% CI 0.57– 0.63). The results were consistent 
in model 2, which also adjusted for clinical factors 
present on admission (aOR 0.70, 95% CI 0.65– 0.72), 
in model 3, which additionally adjusted for hospital 
Figure 3. Result from the subgroup analysis.
IHM indicates invasive hemodynamic monitoring; and OR, odds ratio.
Figure 4. Results of the multivariable risk adjustment analysis
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characteristics (aOR 0.67, 95% CI 0.63– 0.70), in model 
4, which additionally adjusted for temporary MCS (aOR 
0.68, 95% CI 0.64– 0.72), and in model 5, which was 
the most robust Model which included all the previ-
ously mentioned covariates and additionally adjusted 
for the use of advanced heart failure therapy (aOR 
0.69, 95% CI 0.66– 0.73) (Figure  4). The utilization of 
IHM was associated with reduced in- hospital mortality 
regardless of the utilization of advanced heart failure 
therapies (P for interaction=0.86).
In an additional analysis comparing the timing 
of IHM, both early and delayed IHM were associ-
ated with better in- hospital mortality compared to no 
IHM (eIHM=26% versus no IHM=30%, P<0.01) and 
(dIHM=21.5% versus no IHM=29%, P<0.01), respec-
tively. However, after PSM comparing early versus 
delayed IHM, there was no difference between the 2 
in terms of in- hospital mortality (eIHM=22.2% versus 
dIHM=22.7%, P=0.61) (Table 3).
To quantify the strength of any possible unmea-
sured confounder, we calculated the E- Value follow-
ing the methodology of VanderWheel and Ding for 
the primary outcome of in- hospital mortality.20 The 
E- Value (Odds Ratio Scale) for in- hospital mortality 
was 1.7. Thus, our observed reduction in in- hospital 
mortality among patients who were admitted with CS 
and treated with IHM could potentially be explained 
by an unmeasured confounder that was associated 
with both the use of IHM and reduction of in- hospital 
mortality by an OR of 1.7, but weaker confounders 
could not explain this association. Moreover, while 
the primary analysis showed an association between 
IHM use and reduced in- hospital mortality, there 
was no statistical evidence of a spurious associ-
ation between IHM and any of the falsification end 
points used in the current study as follow: catheter- 
associated urinary tract infection (IHM=0.3%, no 
IHM=0.3%, P=0.9) and sacral ulcers (IHM=2.62%, 
no IHM=2.6%, P=0.1).
DISCUSSION
This is the largest contemporary study, using a nation-
ally representative sample of patients with CS, assess-
ing the impact of IHM on clinical outcomes. There are 
several significant findings from our study as follow: (1) 
Among all hospitalized patients with CS, IHM is associ-
ated with a significant reduction in in- hospital mortality, 
(2) the use of IHM is associated with higher utilization 
of advanced heart failure therapies (LVADs and HT), 
(3) IHM is associated with reduced mortality in CS for 
both AMI- CS and non- AMI- CS, (4) the association be-
tween use of IHM and reduced in- hospital mortality 
was consistent among the different subgroups (males 
versus females, White versus non- White, and old ver-
sus young patients) (Figure 5), (5) the IHM group was 
associated with longer length of stay and higher cost 
compared to the no IHM group, and (6) the IHM group 
Table 3. In- Hospital Outcomes Based on Timing of IHM of the Patients Included in Analysis Before and After Propensity 
Score Matching
Variables no. (%)










(n=17 735) Total (n=35 470) P Value
In- hospital outcomes
Death 26.9 21.5 24.7 <0.01 22.2 22.7 22.4 0.61
RRT 8 9.3 8.5 <0.01 8.6 9.2 8.9 0.33
Heart transplant 0.6 1.3 0.9 <0.01 1 1.3 1.1 0.17










(n=30 340) Total (n=60 680) P Value
Death 26.9 35.4 34.7 <0.01 26 30 28 <0.01
RRT 8 8.9 8.8 0.044 8 8.5 8.2 0.36
Heart transplant 0.6 0.5 0.5 0.17 0.6 0.9 0.7 0.052










(n=21 025) Total (n=42 050) P Value
Death 22 35 34.5 <0.01 21.5 29 25.3 <0.01
RRT 9.3 8.9 8.9 0.34 9.3 10 9.6 0.28
Heart transplant 1.3 0.5 0.5 <0.01 1.2 1.3 1.2 0.63
LVADs 5.2 0.8 1.1 <0.01 5.1 2.3 3.7 <0.01
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had a higher percentage of concomitant bloodstream 
infections compared to the no IHM group.
Literature supporting hemodynamic monitoring in CS 
dates as far back as the 1970s.23 Data from the SHOCK 
registry from ≈2 decades back showed that IHM in CS 
provides prognostic information that predicts mor-
tality.24 Contemporary literature from the cardiogenic 
shock working group indicates that IHM can be used 
for phenotyping CS (left ventricular shock, right ven-
tricular shock, or biventricular shock) and guide initial 
triaging, as well as directing timely escalation of phar-
macologic or mechanical support in CS.25- 28 A recent 
study utilized NIS data from 2000 to 2014; the authors 
reported a 75% reduction in IHM over the study period 
and found no reduction in in- hospital mortality in the 
IHM group.10 The differences in the findings between 
our study and the previous analysis can be explained 
by several means. First, our analysis included more 
contemporary data extending from October 2015 
until December 2018. During the study period, there 
have been advances in the care of patients with CS 
after adopting CS treatment algorithms on a national 
scale.5- 7 Secondly, the previous study included only 
patients with AMI- CS. In contrast, in the current anal-
ysis, we included all CS types and performed a sen-
sitivity analysis based on CS type. In another study, 
Hernandez et al specifically studied the role of IHM 
among patients admitted with acute decompensated 
heart failure (ADHF). They showed higher mortality 
with the use of IHM in patients with ADHF without CS.8 
Among patients with CS, IHM’s use was associated 
with lower mortality, consistent with our findings.8 
Moreover, smaller studies from specialized CS cen-
ters showed that the use of IHM among patients with 
AMI- CS is associated with improved survival.5,6
Although an association was observed between IHM 
use in CS and reduced mortality, this does not imply cau-
sality. The IHM- derived invasive hemodynamic monitor-
ing provides essential diagnostic and prognostic data. 
It requires that this data be interpreted accurately and 
coupled with an expeditious and appropriate treatment 
strategy to improve clinical outcomes.2,29 Sionis et al, in 
a study from a European multi- center registry of patients 
with CS, showed that patients who received IHM were 
managed more aggressively, including more frequent 
use of vasopressors, inotropes, and mechanical assist 
Figure 5. Summary of the main findings from the study.
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devices.30 We hypothesize that improvement in survival 
with IHM use in CS is due to earlier recognition, pheno-
typing, and appropriate triaging of patients with CS. This 
approach encourages tailored therapeutic interventions 
directed at the preservation of end- organ function and 
myocardial recovery. Using this strategy of IHM coupled 
with appropriate, timely use of MCS, specialized CS 
centers have shown a dramatic reduction in mortality in 
CS.5,6,7,25 Moreover, consensus documents have also en-
dorsed the routine early use of IHM among all patients 
with CS.2,29
Our analysis showed an association between IHM 
use in CS and higher LVAD and HT utilization. In con-
temporary practice, patients with CS are often stabi-
lized with temporary MCS, and appropriate candidates 
are bridged to definitive advanced therapies including 
durable LVAD or HT.31 Early recognition of evolving CS, 
allowing for interventions aimed to preserve or improve 
failing end- organ function, are paramount in main-
taining physiologic candidacy for definitive advanced 
therapies. Without prompt interventions, multi- organ 
failure may ensue, rendering patients with CS no lon-
ger candidates for advanced therapies. Furthermore, 
IHM informed CS phenotyping helps guide selective 
bridging strategies to definitive therapy.31 For instance, 
an essential benefit of IHM is early recognition of biven-
tricular failure, which is often under- recognized and 
may warrant consideration of bi- ventricular support.26
It is important to note that the current analysis was 
limited to only 3 months of data reflecting the current 
United Network for Organ Sharing (UNOS) HT alloca-
tion scheme (implemented in September 2018). The 
updated UNOS allocation scheme has shifted priority 
from patients supported with durable devices to those 
with temporary mechanical support. A future study in-
corporating more data in the updated UNOS HT allo-
cation scheme will be of interest.
In the contemporary era of robust MCS availabil-
ity, early recognition of CS and IHM- guided therapy is 
critical to prevent progression from hemodynamic in-
sufficiency to profound hemo- metabolic derangement, 
which is invariably associated with higher mortality.32 
Hemodynamic data provided by IHM can confirm 
evolving CS and provide vital information used to cus-
tomize a therapeutic strategy based on severity and 
phenotype. Moreover, IHM provides real- time feed-
back about adequacy of therapy and to determine if 
escalation in pharmacologic or mechanical support is 
warranted.26,29,32
Study Limitations
Our study has several limitations that need to be con-
sidered when interpreting the result from the current 
analysis. First, this is a retrospective observational study 
that is prone to unmeasured confounding variables. 
However, we addressed the unmeasured confound-
ing risk by using PSM, conducting several sensitivity 
analyses, and calculating the strength of the unmeas-
ured confounder needed to change the study results 
(E- Value). Second, this analysis uses billing codes to 
identify procedures and outcomes, and those are 
subject to under- or over- coding. However, we used a 
hard clinical end point for the primary outcome (death), 
which is less prone to coding errors. Third, due to the 
dataset’s inherent limitation, we do not have hemody-
namic, metabolic, or clinical data, which is vital in stag-
ing cardiogenic shock. There is emerging data that the 
efficacy of various therapeutic interventions depends 
on the stage of CS.28 Fourth, the current analysis is 
prone to survivor treatment selection bias. It is likely 
that the sickest patients in extremis (Stage E CS), who 
have the highest mortality, receive fewer diagnostic 
maneuvers like IHM. However, we have accounted for 
that by excluding the patients with severe cardiogenic 
shock who died within 24  hours of admission, thus 
increasing the validity of our study. Furthermore, we 
performed an additional sensitivity analysis excluding 
patients who died within 72 hours from admission to 
reduce the chance of survivor treatment bias. Fifth, the 
NIS database does not provide data on the hospital 
unit (medical intensive care versus cardiac intensive 
care or a step- down unit) and hence could not con-
trol for that in the current analysis. The IHM group may 
be a marker for admission to cardiac intensive care 
units, which are linked to better outcomes, including 
in- hospital mortality among patients with CS.33 Sixth, 
due to the NIS sampling change after the year 2011, it 
is no longer possible to conduct hospital volume analy-
sis. Consequently, we were not able to adjust for that in 
the current analysis. However, we have used hospital 
bed size and teaching status as surrogates for hospital 
volume. Seventh, although we report an association 
between IHM and utilization of advanced heart failure 
therapies, it is well known that right heart catheteriza-
tion is a crucial part of the workup for patients who 
are undergoing elective HT or LVAD. However, we ex-
cluded patients who were admitted electively or pa-
tients who received the IHM after or on the same day 
of receiving LVAD or HT. It is essential to note that the 
current observational nature of the analysis makes it 
hypothesis- generating. The conclusions from the cur-
rent analysis draw attention to the need for further pro-
spective studies to confirm the association between 
IHM use and improved in- hospital mortality among 
patients with CS.
CONCLUSIONS
Among patients admitted with CS, we observed an 
association between IHM utilization and reduced in- 
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higher utilization of advanced heart failure therapies 
(LVADs and HT). The findings suggest that a hemo-
dynamic guided approach to CS management may 
improve survival. Due to the observational nature of 
the current study, the results should be considered 
hypothesis- generating, and future prospective studies 
confirming these findings are needed.
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5A1D70Z, 5A1D80Z,  5A1D90Z,  5A1D60Z, 5A1D00Z 
Left Ventricular Assist 
Device 
02HA0QZ 
Heart Transplant 02YA0Z0, 02YA0Z1 
ECMO 5A1522F,  5A1522G, 5A15A2F, 5A15A2G, 5A15223 
Impella ® pumps 5A0221D, 5A0211D 
IABP 5A02210 
Table S1. International classification of disease-10th 
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